Prosecutors allege that Michael McMillan and Protectus companies used reimbursement-contingent “rebates” or “discounts” to conceal illegal kickbacks, guaranteeing participating healthcare providers substantial profits whenever Medicare and other federal programs paid their skin-substitute wound-care claims
WASHINGTON, DC — Federal prosecutors say Las Vegas businessman Michael McMillan created a skin-substitute sales model that guaranteed participating doctors and other healthcare providers thousands of dollars from successful government reimbursements, while describing those alleged kickbacks as ordinary commercial “rebates” or “discounts.”
The indictment places that terminology at the center of a sprawling healthcare fraud prosecution, alleging that McMillan’s Protectus businesses supplied wound-care products without upfront payment, waited for federal programs to reimburse providers, and then divided the resulting money according to predetermined percentages.
Under the government’s theory, the promised provider share was not a conventional price reduction negotiated independently from insurance payment, because its value allegedly emerged only after Medicare, TRICARE, CHAMPVA, or another government healthcare program approved and paid the corresponding claim.
Prosecutors contend that Protectus commonly collected approximately sixty to seventy percent of each successful reimbursement, while the participating medical provider retained approximately thirty to forty percent, creating what the indictment portrays as a guaranteed profit generated entirely through public healthcare money.
McMillan has not been convicted; every accusation remains unproven, and prosecutors must establish each charged element beyond a reasonable doubt before a jury unless the case concludes through a plea agreement or another lawful judicial resolution.
Why the “Rebate” Label Matters
The Justice Department’s description of rebates matters because legitimate discounts are common in healthcare commerce, yet federal prosecutors can challenge an arrangement when they believe its practical purpose was to reward product orders, recommendations, or referrals reimbursed by government programs.
According to the Northern District of Texas case announcement, McMillan allegedly disguised provider kickbacks as rebates or discounts while Protectus entities received approximately $174 million from claims connected with skin-substitute wound-care products nationwide.
That allegation does not mean every rebate violates federal law, because commercial price reductions may be lawful when properly structured, accurately reported, and supported by legitimate economic substance rather than serving as concealed compensation for federally reimbursed business.
The central courtroom question will instead be whether the Protectus arrangements functioned as genuine product pricing or whether their reimbursement-dependent design deliberately transferred government money to providers as an incentive to select, apply, and bill particular skin substitutes.
A Guarantee Built Around Successful Reimbursement
Prosecutors allege that Protectus offered participating providers products without requiring immediate payment, allowing the doctors, podiatrists, nurse practitioners, and other clinicians to apply the materials before paying the supplier or knowing whether an insurer would approve reimbursement.
If a government program denied the associated claim, the indictment says the provider generally owed Protectus nothing for that product, shifting substantial inventory and collection risk away from the practice while making the supplier’s revenue dependent upon a favorable coverage decision.
When payment arrived, however, Protectus allegedly issued an invoice calculated as a percentage of the reimbursement rather than as a conventional fixed acquisition price, leaving the provider with a substantial remainder that prosecutors characterize as an illegal financial reward.
This structure allegedly aligned the provider and supplier around the same outcome, because both parties received money only when public insurance paid, while a larger reimbursement could increase the amount the clinician retained and Protectus collected.
The indictment further alleges that sales representatives joined this reimbursement chain by earning commissions based upon amounts Protectus received from the providers they had recruited, meaning the government payment allegedly activated compensation across the entire commercial network.
How the Alleged Profit Split Worked
One transaction described by prosecutors allegedly involved a provider receiving $53,625.60 from a reimbursed claim, retaining $16,087.68, and owing Protectus Technologies $37,537.92, producing an exact thirty-to-seventy allocation of the government payment.
That example matters because the government is not simply alleging that Protectus sold a profitable product, but that the supplier and clinician allegedly divided the precise reimbursement after payment according to an agreed formula presented as a rebate.
In another exchange described within the indictment, a provider’s employee reportedly questioned why an invoice left a thirty-five-percent return when a newer agreement promised forty percent, after which McMillan allegedly instructed personnel to correct the calculation.
If authenticated and credited by jurors, such communications could support the prosecution’s contention that provider profit was intentionally guaranteed, although defense lawyers may dispute the records’ context, contractual meaning, authorship, completeness, and relationship to any criminal purpose.
The defense may also argue that percentage-based pricing alone does not establish illegality, especially within a complex reimbursement environment involving delayed payments, product financing, claim denials, credits, disputed invoices, and shifting coverage rules across several federal programs.
A Sales Presentation Allegedly Promoted Provider Profits
During a March 2024 meeting identified by prosecutors, McMillan allegedly explained that Protectus offered medical providers an average rebate of approximately thirty-five percent and used projected Medicare collections to illustrate the monthly income a participating practice could retain.
The presentation allegedly suggested that a practice receiving $180,000 each month from Medicare could keep approximately $63,000 under the arrangement, transforming an abstract discount percentage into a vivid earnings projection that prosecutors may present as evidence of inducement.
Prosecutors also attribute to McMillan a statement that he reviewed Medicare submissions to ensure Protectus products were billed above what providers actually paid, an allegation likely to face close scrutiny over its wording, accuracy, context, and intended meaning.
A sales discussion emphasizing profitability is not automatically criminal, yet the government will probably argue that these statements become more consequential when combined with reimbursement-contingent invoices, provider profit guarantees, claim-form allegations, and commissions tied to successful federal payments.
Defense counsel can respond that informal presentation language cannot substitute for transaction-specific proof, particularly when independent providers, billing personnel, sales representatives, and company employees performed different functions across numerous claims submitted over several years.
Box 19 and the Alleged Acquisition-Price Concealment
The indictment alleges that relevant Medicare claims required disclosure of the provider’s true acquisition price, including discounts, rebates, refunds, and other adjustments, through information entered in Box 19 of the professional healthcare claim form.
Prosecutors say McMillan or Protectus personnel submitted claims, helped providers submit them, or advised them to report prices higher than what clinicians ultimately paid, allegedly preventing Medicare from seeing the reimbursement-dependent reductions built into the commercial arrangement.
In one May 2024 episode, Medicare allegedly paid Medical Provider D $9,024 for one claim and denied another, after which a Protectus employee identified missing Box 19 information, recommended resubmission, and issued a $5,865.60 invoice.
That invoice represented sixty-five percent of the successful claim, according to the indictment, leaving the provider with thirty-five percent and giving prosecutors another transaction connecting reimbursement, invoice timing, acquisition-price disclosure, and the financial benefit the practice retained.
The Box 19 allegations may become especially important because they offer prosecutors a claimed mechanism of deception beyond the payment itself, while defense lawyers can examine whether guidance was clear, material, consistently applied, and personally understood by McMillan.
Providers Allegedly Received About $94 Million
Across the full charged period, prosecutors estimate that participating medical providers retained approximately $94 million from reimbursements associated with Protectus products, a figure the government characterizes as kickbacks generated through the disputed rebate and discount arrangements.
Protectus entities allegedly received approximately $174 million after the providers kept their negotiated shares, while Medicare and other federal healthcare benefit programs paid approximately $268 million on claims that prosecutors now describe as false, fraudulent, or tainted by illegal remuneration.
Those totals reflect allegations from the government’s investigation rather than final judicial findings, and any eventual loss or restitution calculation could involve disputes over legitimate treatment, product value, claim eligibility, patient benefit, and payments attributable to particular conduct.
The arithmetic nevertheless explains why the rebate theory matters so much to the case, because prosecutors contend that nearly every dollar flowing through the arrangement was divided according to incentives that rewarded federally reimbursed product use.
Sales Representatives Allegedly Collected Another $27 Million
McMillan allegedly recruited sales representatives to locate medical providers, explain the profit-sharing model, and expand the Protectus network, while calculating representative compensation from company receipts associated with claims generated by the practices those representatives introduced.
Prosecutors estimate that Protectus paid approximately $27 million to sales representatives, in addition to the approximately $94 million allegedly retained by providers, demonstrating how widely the government believes reimbursement-linked compensation extended throughout the organization.
A November 2022 email exchange cited in the indictment reportedly concerned a representative commission report worth $44,035.92 and an alleged omission exceeding $6,400, while a company employee explained that commissions followed insurer payment to the provider.
The commission evidence could help prosecutors portray the operation as a coordinated referral machine, although the defense may distinguish permissible employee compensation from payments to independent marketers and challenge whether individual representatives actually induced federally reimbursed orders.
Protectus Companies and a Multistate Provider Network
The indictment identifies Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC as businesses McMillan allegedly owned or controlled during the charged conduct.
Prosecutors place the alleged scheme between approximately May 2019 and February 2026, providing investigators with years of contracts, invoices, reimbursement reports, billing communications, commission calculations, bank records, and asset transactions spanning multiple states.
Five anonymized providers described in the indictment allegedly practiced in Arlington, Dallas, and McKinney, Texas, as well as Santa Monica, California, and Payson, Utah, linking McMillan’s Nevada-based corporate network to healthcare activity in the Northern District of Texas.
That geographic reach also illustrates why a Nevada businessman faces prosecution in North Texas, where prosecutors can establish venue through alleged conspiratorial acts, provider relationships, affected claims, financial transactions, or other legally significant conduct occurring within the district.
Nine Counts and Several Distinct Legal Theories
Count One charges conspiracy to commit healthcare fraud, while Count Two alleges a conspiracy to defraud the United States and offer or pay illegal healthcare kickbacks and bribes through the disputed skin-substitute sales and reimbursement arrangements.
Counts Three through Nine accuse McMillan of conducting monetary transactions exceeding $10,000 with property allegedly derived from specified unlawful activity, focusing upon seven purchases or transfers prosecutors contend involved proceeds from the charged conspiracies.
Those transactions allegedly concern real estate connected with Dallas, Las Vegas, Simpsonville in Kentucky, and Del Mar in California, together with a 2023 Lamborghini Urus, a 2023 Cadillac Escalade, and a Cessna Citation VII aircraft.
Federal authorities reported seizing assets valued at approximately $35 million, but seizure does not establish guilt or permanent forfeiture, and later proceedings may address ownership, tracing, lawful income, third-party interests, substitute assets, valuations, and constitutional proportionality.
An NBC 5 Dallas-Fort Worth report examining the newly unsealed cases said prosecutors alleged approximately $94 million reached providers and another $27 million reached representatives, while also detailing luxury property and vehicle accusations connected with McMillan.
When a Discount Can Become Prosecutorial Evidence
The federal Anti-Kickback Statute broadly targets knowing and willful remuneration intended to induce or reward certain referrals, recommendations, purchases, or orders involving federally reimbursable items or services, although statutory exceptions and regulatory safe harbors can protect qualifying arrangements.
Because commercial discounts can reduce healthcare costs, federal law does not treat every rebate as suspicious; however, arrangements generally require careful structuring, transparent accounting, accurate reporting, and documentation showing that price adjustments are genuine rather than concealed inducements.
The McMillan prosecution tests the boundary through several combined allegations, including no payment after denied claims, invoices generated only after reimbursement, percentage-based provider profits, sales commissions tied to collections, and claimed misstatements concerning actual acquisition cost.
Prosecutors will likely argue that these features reveal a unified purpose that contractual vocabulary cannot sanitize, while the defense can insist that lawful commercial risk-sharing should not be converted into criminal intent through hindsight or selective interpretation.
Jurors may therefore hear competing explanations of the same spreadsheets, invoices, contracts, and emails, with the government describing a concealed kickback formula and the defense portraying legitimate commerce operating within an unusually complicated reimbursement system.
Why the Allegations Matter for Patient Care
Skin substitutes can benefit appropriately selected patients with chronic or difficult wounds, but unusually large reimbursement margins can create financial pressure that affects product selection, application size, treatment frequency, and decisions about whether a patient should receive advanced therapy.
The McMillan indictment primarily emphasizes alleged kickbacks and acquisition-price representations rather than declaring every application medically unnecessary, meaning public discussion should not assume that every patient, provider, employee, or transaction associated with Protectus was culpable.
Even when treatment offers clinical value, prosecutors can argue that hidden remuneration corrupted independent medical judgment or made resulting claims ineligible, while the defense can challenge whether physicians selected products based upon genuine patient needs and documented coverage criteria.
The distinction is important because healthcare enforcement should protect beneficiaries without stigmatizing legitimate wound care, particularly when chronic ulcers, diabetes, infection, vascular disease, immobility, and amputation risks make timely access to effective treatment medically consequential.
Part of the 2026 National Healthcare Fraud Takedown
McMillan’s indictment formed part of the 2026 National Health Care Fraud Takedown, which federal officials said produced charges against 455 defendants, including ninety doctors and other licensed professionals, across alleged schemes involving more than $6.5 billion in false claims.
The coordinated initiative spanned fifty-six federal districts and forty-five states and territories, with all fifty-state Medicaid Fraud Control Units participating, and federal authorities reported seizing more than $182 million in cash, vehicles, jewelry, and other property.
Within the Northern District of Texas, thirteen defendants faced seven separate cases involving more than $365 million in alleged fraudulent billing, with McMillan’s approximately $268 million wound-care prosecution representing the district’s largest announced matter by claimed payment value.
The district’s other cases involved laboratory testing, transcranial magnetic stimulation, electroencephalography, hospice services, unsolicited coronavirus test kits, and durable medical equipment, showing that authorities targeted multiple reimbursement pathways during the same coordinated enforcement campaign.
Compliance Lessons for Wound-Care Businesses
Manufacturers, distributors, medical practices, and marketers should examine the economic substance of discounts rather than relying upon reassuring labels, because a rebate can create exposure when its amount, timing, or availability allegedly rewards federally reimbursed business.
Compliance reviewers should determine whether invoices remain payable after denied claims, whether providers receive guaranteed margins, whether acquisition prices include every adjustment, whether sales compensation tracks reimbursement, and whether billing assistance prevents clinicians from independently verifying submitted information.
Companies should also preserve contracts, messages, invoices, claim records, commission reports, training materials, and pricing policies when concerns emerge, because retroactive revisions, missing communications, or inconsistent explanations can magnify investigative and reputational consequences.
When criminal allegations become public, disciplined crisis public-relations management can help affected organizations separate charges from established facts, preserve patient confidentiality, coordinate accurate stakeholder communications, and avoid impulsive statements that create additional legal exposure.
Reputational Damage Arrives Before a Verdict
An indictment can immediately dominate search results, disrupt provider relationships, unsettle employees, frighten patients, and undermine commercial confidence, even though discovery, expert analysis, pretrial motions, trial preparation, and possible appeals may require several years.
Organizations confronting that imbalance may require carefully documented reputation-rebuilding strategies that correct demonstrable inaccuracies, publish responsible procedural updates, explain compliance reforms, and maintain consistent communications without concealing material facts or prejudging the judicial process.
Credible public messaging should distinguish what prosecutors allege, what defense counsel disputes, what evidence has entered the record, and what remains unknown, because exaggerated denials can become as damaging as uncritical repetition of unproven accusations.
Protectus, associated providers, employees, representatives, and third parties may face different legal and reputational positions, making individualized communications essential whenever public statements could imply guilt, reveal protected information, or interfere with ongoing litigation.
What Happens Next in Federal Court
Pretrial litigation may examine electronic communications, reimbursement records, claim forms, contract interpretation, product invoices, financial tracing, search procedures, expert testimony, witness credibility, and the contested legal boundary separating legitimate discounts from prohibited remuneration.
Prosecutors must prove McMillan knowingly joined the charged conspiracies and possessed the required awareness for each alleged monetary transaction, while defense lawyers can challenge intent, materiality, loss calculations, attribution, statutory interpretation, and the reliability of cooperating witnesses.
Any eventual sentencing analysis following convictions would depend upon the statutes sustained, advisory guidelines, criminal history, accepted responsibility, proven loss, role findings, obstruction questions, recovered property, victim evidence, and other individualized considerations evaluated by the presiding judge.
The government’s rebate theory will ultimately succeed or fail based on admissible evidence showing how Protectus agreements operated, what McMillan understood, what providers were promised, what claims were disclosed, and why disputed payments moved between federal programs, clinics, representatives, and companies.
Until a jury returns verdicts or another lawful resolution concludes the prosecution, Michael McMillan remains presumed innocent, the approximately $268 million payment figure remains an allegation, and every disputed rebate, invoice, commission, and transaction remains subject to adversarial testing.
